What is the role of the modified ROX (Rapid Oxygenation and Weaning) index in predicting extubation success in adult patients with respiratory failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Modified ROX Index in Extubation

The modified ROX index incorporating heart rate (ROX-HR) is a validated tool for predicting extubation success when high-flow nasal cannula (HFNC) therapy is used post-extubation, with a ROX-HR >6.80-8.00 at 2-10 hours post-extubation significantly associated with lower risk of HFNC failure and need for reintubation. 1

What is the Modified ROX Index?

The modified ROX index builds upon the original ROX index by incorporating heart rate to improve predictive accuracy:

  • Original ROX Index = (SpO₂/FiO₂) / Respiratory Rate 2
  • Modified ROX-HR Index = (ROX Index / Heart Rate) × 100 1
  • ROX-HR-Flow Index = Further incorporates HFNC flow rate and substitutes PaO₂/FiO₂ for SpO₂/FiO₂ 3

The ROX-HR index demonstrates superior predictive performance compared to the standard ROX index, particularly in the post-extubation setting where it remains significantly associated with HFNC failure at all time points between 1-24 hours. 1

Clinical Application Algorithm

Timing of Measurements

Measure the modified ROX-HR index at these critical time points after HFNC initiation post-extubation:

  • 2 hours: ROX-HR-Flow >12.25 predicts HFNC success (sensitivity 77.6%, specificity 85.7%) 3
  • 10 hours: ROX-HR >6.80 for acute respiratory failure patients; >8.00 for post-extubation patients predicts lower risk of failure 1
  • 12 hours: Standard ROX >10.4 remains predictive 4

The ROX-HR-Flow index at 2 hours post-HFNC initiation demonstrates the best prediction accuracy (AUROC 0.854) for early identification of treatment failure. 3

Decision Thresholds for Post-Extubation HFNC

High Risk of Failure (Consider Reintubation):

  • ROX-HR <6.80 at 10 hours post-extubation 1
  • ROX-HR-Flow <12.25 at 2 hours post-extubation 3
  • Standard ROX <8.7 at 2-6 hours or <10.4 at 12 hours 4

Low Risk of Failure (Continue HFNC):

  • ROX-HR >8.00 at 10 hours (hazard ratio 0.176 for failure) 1
  • ROX-HR-Flow >12.25 at 2 hours 3
  • Standard ROX >8.7 at 2-6 hours or >10.4 at 12 hours 4

Integration with Standard Extubation Assessment

While the modified ROX index is valuable for post-extubation HFNC management, it must be used alongside standard extubation readiness criteria:

Pre-Extubation Assessment (Required First):

  • Complete 30-minute spontaneous breathing trial successfully 5
  • Assess upper airway patency, bulbar function, sputum load, and cough effectiveness 5
  • Perform cuff leak test in high-risk patients (intubation >6 days, traumatic intubation, female sex, large endotracheal tube) 5, 6
  • Administer systemic corticosteroids at least 4-6 hours before extubation if cuff leak test is positive 6

Post-Extubation Monitoring:

  • Initiate HFNC therapy in high-risk patients immediately after extubation 7
  • Calculate modified ROX-HR or ROX-HR-Flow index at 2,6,10, and 12 hours 3, 1
  • Monitor for early failure signs: capacity-load imbalance, impaired bulbar function, ineffective cough, cardiac dysfunction 5, 7

Comparative Performance of Modified Indices

ROX-HR-Flow demonstrates superior early prediction compared to standard ROX or ROX-HR alone, particularly within the first 2 hours post-extubation. 3 This allows earlier identification of patients at risk for HFNC failure and potential need for reintubation.

The standard ROX index prediction accuracy increases over time (AUROC: 2h=0.679, 6h=0.703, 12h=0.759), but the modified indices incorporating heart rate show better discrimination at earlier time points. 2, 1

Additional Predictive Factors

Integrate these factors with modified ROX index for comprehensive assessment:

  • Respiratory Insufficiency (RI) Index >20 at 1 hour post-extubation independently predicts failure (OR 4.50) 8
  • Modified Early Warning Score (MEWS) >4 at 1 hour post-extubation independently predicts failure (OR 4.01) 8
  • Age >60 years increases risk of extubation failure (OR 3.89) 8
  • Sex, BMI, and total ventilator duration should be considered in integrated models 4

Critical Caveats

The modified ROX index specifically predicts HFNC therapy outcomes, not general extubation success. It should only be applied to patients receiving HFNC post-extubation, not those extubated to room air or standard oxygen therapy. 1, 4

Do not delay reintubation based solely on borderline ROX values if clinical deterioration is evident. The index helps identify risk but does not replace clinical judgment regarding respiratory distress, hemodynamic instability, or neurological decline. 7

Validation studies were primarily conducted in pneumonia patients (86.9% of cohorts), so applicability to other populations (post-operative, cardiac, neuromuscular disease) requires caution. 1, 2

The ROX index components (SpO₂/FiO₂ ratio) carry greater weight than respiratory rate in the calculation, so ensure accurate FiO₂ delivery and SpO₂ measurement. 2

References

Related Questions

What is the significance of ROX (Respiratory Oxygenation) index scoring in High-Flow Nasal Oxygen (HFNO) therapy?
What is the ROX index (ratio of SpO₂/FiO₂ to respiratory rate) in oxygen therapy?
What are the guidelines for initiating and managing high flow nasal cannula (HFNC) therapy in patients with respiratory distress?
How to wash out carbon dioxide on High Flow Nasal Cannula (HFNC)?
What questions should I ask and physical examination findings should I look for in a 3-year-old female patient currently on High Flow Nasal Cannula (HFNC) at 1L/kg with 25% Fraction of Inspired Oxygen (FiO2)?
What are the possible side effects of the rabies vaccine (inactivated rabies vaccine, e.g., Imovax (Human Diploid Cell Vaccine) or RabAvert (Purified Chick Embryo Cell Vaccine)) on a pregnant woman with compromised health status?
What is the appropriate management for a 48-year-old male with knee joint pain and hyperuricemia (elevated uric acid level)?
What is the population of study for the predictive value of the modified ROX (Rapid Shallow Breathing) index in adult patients with respiratory failure in intensive care units (ICUs)?
Are there any complications in pregnancy for pregnant women who receive the rabies (Rabies Immunoglobulin) vaccine during pregnancy?
How is thrombocytopenia (low platelet count) managed in a pregnant patient?
How to proceed with a donor embryo transfer in a patient with primary infertility, an endometrium thickness of 9.5 mm on day 4, an 11 mm ovarian cyst, and a mildly adenomyotic uterus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.